Progress in individualized， precise and comprehensive treatment of esophageal cancer

doi:10.3760/cma.j.cn371439-20250415-00044

Abstract

Abstract:

The comprehensive treatment of esophageal cancer has undergone tremendous changes with the advent of the era of targeted and immunotherapy. The optimization of comprehensive treatment strategies will become increasingly precise with the deep research on biomarkers related to the therapeutic effect of esophageal cancer. With the precise implementation of various treatment methods， the therapeutic effect of esophageal cancer is bound to be significantly improved.

Key words: Esophageal neoplasms, Personalized precision therapy, Biomarkers， tumor, Combined modality therapy

Yi Yan, Li Baosheng. Progress in individualized， precise and comprehensive treatment of esophageal cancer[J]. Journal of International Oncology, 2025, 52(5): 257-261.

References 41

[1]	Liu CQ, Ma YL, Qin Q, et al. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040[J]. Thorac Cancer, 2023, 14(1): 3-11. DOI: 10.1111/1759-7714.14745.
[2]	Shah MA, Sun JM, Shen L, et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study[J]. J Clin Oncol, 2024, 42(3_suppl): 250-250. DOI: 10.1200/JCO.2024.42.3_suppl.250.
[3]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
[4]	Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial[J]. Nat Med, 2024, 30(9): 2549-2557. DOI: 10.1038/s41591-024-03064-w. pmid: 38956195
[5]	Leng X F, He W, Lyu J H, et al. Preliminary results from the multicenter, randomized phase Ⅲ trial (SCIENCE): comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma[J]. J Clin Oncol, 2025, 43(4 Suppl): LBA329. DOI: 10.1200/JCO.2025.43.4_suppl.LBA329.
[6]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
[7]	Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J]. N Engl J Med, 2022, 386(5): 449-462. DOI: 10.1056/NEJMoa2111380.
[8]	Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors[J]. J Clin Oncol, 2023, 41(12): 2181-2190. DOI: 10.1200/JCO.22.01351.
[9]	Wang HH, Steffens EN, Kats-Ugurlu G, et al. Potential predictive immune and metabolic biomarkers of tumor microenvironment regarding pathological and clinical response in esophageal cancer after neoadjuvant chemoradiotherapy: a systematic review[J]. Ann Surg Oncol, 2024, 31(1): 433-451. DOI: 10.1245/s10434-023-14352-z.
[10]	Liu Z, Zhang Y, Ma N, et al. Progenitor-like exhausted SPRY1⁺ CD8⁺ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma[J]. Cancer Cell, 2023, 41(11): 1852-1870.e9. DOI: 10.1016/j.ccell.2023.09.011.
[11]	Kim SP, Vale NR, Zacharakis N, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors[J]. Cancer Immunol Res, 2022, 10(8): 932-946. DOI: 10.1158/2326-6066.CIR-22-0040. pmid: 35749374
[12]	Moding EJ, Nabet BY, Alizadeh AA, et al. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease[J]. Cancer Discov, 2021, 11(12): 2968-2986. DOI: 10.1158/2159-8290.CD-21-0634. pmid: 34785539
[13]	Qiu B, Guo W, Zhang F, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC[J]. Nat Commun, 2021, 12(1): 6770. DOI: 10.1038/s41467-021-27022-z.
[14]	Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients[J]. Science, 2021, 371(6529): 602-609. DOI: 10.1126/science.abb5920. pmid: 33303685
[15]	Chen YX, Wang ZX, Jin Y, et al. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma[J]. Cancer Cell, 2023, 41(5): 919-932.e5. DOI: 10.1016/j.ccell.2023.03.016.
[16]	Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. DOI: 10.1016/S0140-6736(10)61121-X.
[17]	Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382(25): 2419-2430. DOI: 10.1056/NEJMoa2004413.
[18]	Cao Q, Li Y, Li Z, et al. Development and validation of a radiomics signature on differentially expressed features of ¹⁸F-FDG PET to predict treatment response of concurrent chemoradiotherapy in thoracic esophagus squamous cell carcinoma[J]. Radiother Oncol, 2020, 146: 9-15. DOI: 10.1016/j.radonc.2020.01.027.
[19]	Li Z, Han C, Wang L, et al. Prognostic value of texture analysis based on pretreatment DWI-weighted MRI for esophageal squamous cell carcinoma patients treated with concurrent chemo-radiotherapy[J]. Front Oncol, 2019, 9: 1057. DOI: 10.3389/fonc.2019.01057. pmid: 31681593
[20]	Li X, Gao H, Zhu J, et al. 3D deep learning model for the pretreatment evaluation of treatment response in esophageal carcinoma: a prospective study (ChiCTR2000039279)[J]. Int J Radiat Oncol Biol Phys, 2021, 111(4): 926-935. DOI: 10.1016/j.ijrobp.2021.06.033.
[21]	An D, Cao Q, Su N, et al. Response prediction to concurrent chemoradiotherapy in esophageal squamous cell carcinoma using delta-radiomics based on sequential whole-tumor ADC map[J]. Front Oncol, 2022, 12: 787489. DOI: 10.3389/fonc.2022.787489.
[22]	Li X, Dong J, Li B, et al. Prediction of neoadjuvant chemoradiotherapy sensitivity in patients with esophageal squamous cell carcinoma using CT-based radiomics combined with clinical features[J]. Dose Response, 2024, 22(4): 15593258241301525. DOI: 10. 1177/15593258241301525.
[23]	Feng L, Zhao K, Sun L, et al. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis[J]. J Transl Med, 2021, 19(1): 367. DOI: 10.1186/s12967-021-03042-7.
[24]	Yin X, Tian M, Zhang J, et al. MiR-26b-5p in small extracellular vesicles derived from dying tumor cells after irradiation enhances the metastasis promoting microenvironment in esophageal squamous cell carcinoma[J]. Cancer Lett, 2022, 541: 215746. DOI: 10.1016/j.canlet.2022.215746.
[25]	Zheng C, Li Z, Zhao C, et al. YY1 modulates the radiosensitivity of esophageal squamous cell carcinoma through KIF3B-mediated Hippo signaling pathway[J]. Cell Death Dis, 2023, 14(12): 806. DOI: 10.1038/s41419-023-06321-x.
[26]	Li M, Zhang Z, Wang Q, et al. Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics[J]. Nat Commun, 2022, 13(1): 5268. DOI: 10. 1038/s41467-022-32962-1.
[27]	Wada Y, Kumagai S, Takagi N, et al. Definitive-dose adjuvant radiotherapy following endoscopic submucosal dissection for superficial esophageal cancer[J]. J Gastroenterol, 2025, 60(1): 32-42. DOI: 10.1007/s00535-024-02156-1.
[28]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[29]	Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 rando-mized clinical trial[J]. JAMA Surg, 2021, 156(8): 721-729. DOI: 10.1001/jamasurg.2021.2373.
[30]	Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J]. Ann Surg Oncol, 2012, 19(1): 68-74. DOI: 10.1245/s10434-011-2049-9. pmid: 21879261
[31]	van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2025, 26(4): 425-436. DOI: 10.1016/S1470-2045(25)00027-0.
[32]	Bando H, Kumagai S, Kotani D, et al. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma-a multicenter phase 2 trial (EPOC1802)[J]. Nat Cancer, 2025, 6(3): 445-459. DOI: 10.1038/s43018-025-00918-1.
[33]	Zhang W, Yan C, Gao X, et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma[J]. Oncologist. 2021, 26(7): e1110-e1124. DOI: 10.1002/onco.13797.
[34]	Zhang W, Yan C, Zhang T, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study[J]. Oncoimmunology, 2021, 10(1): 1971418. DOI: 10.1080/2162402X.2021.1971418.
[35]	He M, Wang Z, Lu J, et al. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial[J]. Med, 2024, 5(9): 1137-1149.e3. DOI: 10.1016/j.medj.2024.05.008. pmid: 38870932
[36]	Zhang YP, Guo ZQ, Cai XT, et al. PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy[J]. Cancer Cell, 2025, 43(5): 856-874.e9. DOI: 10.1016/j.ccell.2025.02.024.
[37]	Piffkó A, Yang K, Panda A, et al. Radiation-induced amphiregulin drives tumour metastasis[J/OL]. Nature, [2025-04-14]. DOI: 10. 1038/s41586-025-08994-0.
[38]	Zhang J, Li M, Zhang K, et al. Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: a randomized, multicenter, phase Ⅲ clinical trial[J]. Cancer Commun (Lond), 2024, 44(10): 1173-1188. DOI: 10.1002/cac2.12601.
[39]	Meng X, Wu T, Hong Y, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 245-253. DOI: 10. 1016/S2468-1253(21)00378-2.
[40]	Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. DOI: 10.1200/JCO.20.01888.
[41]	Huang S, Li Z, Gao Z, et al. Effect of immunochemotherapy infusion timing, sequence, and interval on prognosis of advanced esophageal cancer: a retrospective cohort study[J]. Int J Surg, 2025, 111(1): 1596-1600. DOI: 10.1097/JS9.0000000000002085.